How is Delic creating a legal psychedelic ecosystem

In 2019, a new kind of wellness business sprouted – a legal psychedelic drug company. We spoke with Matt Stang, the co-founder and CEO of Delic Corp to learn more about their mission as well as any strategies they utilized to build a publicly traded, legal psychedelic ecosystem. Matt Stang spent twenty years pioneering the […]

The post How is Delic creating a legal psychedelic ecosystem appeared first on Latest Cannabis News Today – Headlines, Videos & Stocks.

Ketamine: Leading the Race of Psychedelic-Based Therapy

With psilocybin on the rise as a natural option to traditional therapy, Ketamine is now leading the race of psychedelic-based therapy. Approved by the FDA as an anesthetic in 1970, it is used for pain control during surgeries and to decrease postoperative pain in human and veterinary medicine. Make no mistake – these are not […]

The post Ketamine: Leading the Race of Psychedelic-Based Therapy appeared first on Latest Cannabis News Today – Headlines, Videos & Stocks.

Treating addictions with psychedelic psychotherapy

Imagine having a treatment-resistant addition. You’ve tried going to therapy, taking medications, receiving treatment at rehabilitation centres–everything. But none of it worked. Where do you even go from there? What else is there to do? Getting an addiction can not only hinder one’s mental and physical health, but also their relationships, career, and life in […]

The post Treating addictions with psychedelic psychotherapy appeared first on Latest Cannabis News Today – Headlines, Videos & Stocks.

Wednesday, March 11, 2020 Headlines | Marijuana Today Daily News

Marijuana Today Daily Headlines
Wednesday, March 11, 2020 | Curated by host Shea Gunther

// The CDC’s coronavirus failure was predicted by its VAPI response (Leafly)

// Mississippi Medical Marijuana Measure At Risk After House Approves Alternate Ballot Question (Marijuana Moment)

// Iowa House passes bill changing THC limit in state’s medical marijuana program (Des Moines Register)


These headlines are brought to you by MJToday Media, publishers of this podcast as well as our weekly show Marijuana Today and the most-excellent Green Rush Podcast. And check out our new show Weed Wonks!


// FDA Invites The Public To Submit More Comments On CBD (Marijuana Moment)

// California passes $1 billion in cannabis tax revenue two years after launching legal market (OC Register)

// Columbia Care Reports $23 Million Revenue in Q4 and Sees 2020 Exceeding $155 Million (New Cannabis Ventures)

// The Green Organic Dutchman Takes $127 Million Charge In Fourth Quarter (Green Market Report)

// NJ medical marijuana: State’s top court says patients can’t be fired (North Jersey)

// Canada Defends Marijuana Legalization In Response To International Skepticism (Marijuana Moment)

// Toronto’s New Ketamine Clinic Offers Treatment by Tripping Through K-Holes (Merry Jane)


Check out our other projects:
Marijuana Today— Our flagship title, a weekly podcast examining the world of marijuana business and activism with some of the smartest people in the industry and movement.
Marijuana Media Connect— A service that connects industry insiders in the legal marijuana industry with journalists, bloggers, and writers in need of expert sources for their stories.

Love these headlines? Love our podcast? Support our work with a financial contribution and become a patron.

Photo: 葉 正道 Ben/Flickr

Wednesday, March 11, 2020 Headlines | Marijuana Today Daily News

Marijuana Today Daily Headlines
Wednesday, March 11, 2020 | Curated by host Shea Gunther

// The CDC’s coronavirus failure was predicted by its VAPI response (Leafly)

// Mississippi Medical Marijuana Measure At Risk After House Approves Alternate Ballot Question (Marijuana Moment)

// Iowa House passes bill changing THC limit in state’s medical marijuana program (Des Moines Register)


These headlines are brought to you by MJToday Media, publishers of this podcast as well as our weekly show Marijuana Today and the most-excellent Green Rush Podcast. And check out our new show Weed Wonks!


// FDA Invites The Public To Submit More Comments On CBD (Marijuana Moment)

// California passes $1 billion in cannabis tax revenue two years after launching legal market (OC Register)

// Columbia Care Reports $23 Million Revenue in Q4 and Sees 2020 Exceeding $155 Million (New Cannabis Ventures)

// The Green Organic Dutchman Takes $127 Million Charge In Fourth Quarter (Green Market Report)

// NJ medical marijuana: State’s top court says patients can’t be fired (North Jersey)

// Canada Defends Marijuana Legalization In Response To International Skepticism (Marijuana Moment)

// Toronto’s New Ketamine Clinic Offers Treatment by Tripping Through K-Holes (Merry Jane)


Check out our other projects:
Marijuana Today— Our flagship title, a weekly podcast examining the world of marijuana business and activism with some of the smartest people in the industry and movement.
Marijuana Media Connect— A service that connects industry insiders in the legal marijuana industry with journalists, bloggers, and writers in need of expert sources for their stories.

Love these headlines? Love our podcast? Support our work with a financial contribution and become a patron.

Photo: 葉 正道 Ben/Flickr

The Ketamine Clinic Craze: Legalities and Possibilities

In recent years, the United States has seen a proliferation of ketamine clinics. From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs.

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine. Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here).

With respect to ketamine infusion therapy (which is the prime time attraction of ketamine clinics), the medical research based promise is for treatment of chronic neuropathic pain, chronic pain (instead of opioids), and various medication-resistant mental health disorders, including depression, bi-polar disorder, and PTSD (among others). According to the American Psychiatric Nurses Association:

Ketamine infusion therapy involves the administration of a single infusion or a series of infusions for the management of psychiatric disorders (e.g., major depressive disorder, post-traumatic stress disorder, acute suicidality). Ketamine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that has traditionally been used for the induction and maintenance of anesthesia.

Still, for all its promise, would-be clinic owners, practitioners, and consumers may be confused about the legality of such clinics. There are questions about the logistics of opening and running one of these types of businesses, given the complex interplay of laws and regulations promulgated by bodies from the U.S. Food and Drug Administration (FDA) to cities and counties. This post is dedicated to clearing up some of the confusion behind ketamine clinic set-up and operation.

What are the exact legalities behind ketamine?

Sine 1970, ketamine has only been approved by the FDA for the induction and maintenance of anesthesia. However,  it is also being used for off-label infusions for the management of psychiatric disorders and chronic pain management (enter the clinics). The FDA doesn’t have any regulations on point for the control and oversight of ketamine clinics when it comes to infusion therapy and the states don’t really either.

In 1999, the Drug Enforcement Administration (DEA) listed ketamine as a Schedule III controlled substance (a depressant) pursuant to the Controlled Substances Act, which means it has a moderate to low abuse potential (lower than Schedules I and II), a currently accepted medical use, and a low to moderate potential for physical or psychological dependence. Ketamine makes its home on Schedule III alongside anabolic steroids and testosterone. According to the Feds, ketamine is safer than cannabis (which is a Schedule I controlled substance).

So, how does one lawfully open and operate a ketamine clinic for infusion therapy given the foregoing?

First, ketamine infusion therapy is an off-label use for ketamine in the U.S. “Off-label use” (which is extremely common) is:

the use of pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration. Both prescription drugs and over-the-counter drugs (OTCs) can be used in off-label ways, although most studies of off-label use focus on prescription drugs.

According to the FDA, “once the FDA approves a drug, healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient.” Oftentimes, a healthcare provider may prescribe a drug off-label because there might not be an approved drug out there yet to treat the subject medical condition or because no other medication has worked yet for the patient.

Ketamine infusion therapy fits squarely into legitimate off-label use for those mental health conditions not effectively treated by what’s on the pharmaceutical market today (and there are definitely more treatment possibilities out there as medical research continues). And as long as the healthcare provider in charge judges the infusion therapy to be ethical and not violative of safety standards, they may prescribe it accordingly.

Second, ketamine is still a controlled substance even if it’s being used for off-label administration, so you still have to follow all federal and state laws around Schedule III registration, storage, inventory management, security, record keeping, and prescription protocols (which is not insignificant). Whomever on site is administering, manufacturing, storing, or distributing the drug, from the doctor to the nurse practitioner to the on-site pharmacist, must register with the DEA in accordance with Part 1301 of Title 21 of the Code of Federal Regulations on and after August 12, 1999.  Failure to follow these very specific legal directives can lead to immediate criminal liability under federal law.

Third, multiple existing and state laws and regulations will apply to a ketamine clinic. Specifically, clinics should analyze state (and federal) medical, drug and facility statutes and regulations to identify various regulatory barriers to entry. Local laws will also likely come into play regarding the licensing and permitting of the clinic within certain zones of a city’s or county’s borders.

Fourth, because there is no FDA regulation on point for the control and oversight of ketamine clinics, it’s “dealer’s choice” on how the business is operated– including patient safety protocols. Because of this, multiple medical community interest groups have established recommended business and patient protocols to ensure that these clinics are abiding by a variety of ethical and corporate standards for ultimate patient care. See, for example, this comprehensive ketamine infusion therapy checklist developed by the American Association of Nurse Anesthetists.

Fifth, given that ketamine infusion therapy is still an off-label use, the liabilities for ketamine clinics is fairly far-reaching. The consequences of medical malpractice may be greater because of the off-label use of the drug; dosing and frequency of treatments, marketing and promotions, medical claims and statements of efficacy, patient screening and determination of appropriateness of administration, and coordination with mental health care providers (to name just a few) are going to be areas of vulnerability as a result.

Despite the growing body of research behind ketamine as an effective treatment for certain mental health issues and mood disorders, in 2017, an American Psychiatric Association (APA) task force related to ketamine cautioned medical practitioners (in a consensus statement) around the expanding use of the drug as an off-label treatment.

Ketamine is also widely known as a popular party drug (“Special K“). If a clinic is not scrupulous regarding its patient population and intake procedures (using minimal screening and untrained providers), or is looking to make a buck over a growing medical fad, anyone could get access to ketamine infusions. That access would be available under the auspices of having a chronic, untreatable mood disorder. As such, legitimate concerns also exist that legitimate patients won’t get enough of the treatment or they’ll get too much of the drug to their detriment.

Finally, esketamine nasal spray (a derivative of ketamine) was separately approved by the FDA for treatment-resistant depression last year. The new drug’s name is Spravato and its maker is Janssen, a division of Johnson & Johnson. On the back of this FDA approval, I can only imagine that more and more clinics will open across the nation, utilizing Spravato and continuing to explore off-label uses and applications of ketamine (especially since neither the FDA or DEA have really cracked down on these clinics).

Be sure to stay tuned as this exciting area of emerging medicine evolves.